jupiter trial
TRANSCRIPT
JUPITEROVMC LANDMARK TRIALS SERIES
Ridker PM, et al. "Rosuvastatin to prevent vascular events in men and women with elevated C-reactive
protein". The New England Journal of Medicine. 2008. 359(21):2195-2207.
The Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin
(JUPITER)
BACKGROUND High level of inflammatory biomarker C-
reactive protein can predict future vascular events
Statins lower levels of CRP as well as cholesterol
Sometimes cardiovascular events can still occur in patients with normal LDL cholesterol
The JUPITER trial seeks to assess if statin can benefit patients without hyperlipidemia but with elevated CRP levels
CLINICAL QUESTION
In patients with normal LDL and elevated high-sensitivity CRP (HS-CRP), does
rosuvastatin reduce the incidence of major CV events?
DESIGN
Analysis: Intention-to-treat Multicenter, double-blind, parallel-group, randomized, placebo-controlled trial N=17,802 patients with normal LDL and elevated HS-CRP
Rosuvastatin (n=8,901) Placebo (n=8,901)
Setting: 1315 centers in 26 countries Enrollment: 2003-2006 Median follow-up: 1.9 years Primary outcome: Combined endpoint of first major CV event
POPULATION
Inclusion Criteria Men >50 years, or women >60 years LDL <130 mg/dL HS-CRP >2.0 mg/L Triglycerides <500 mg/dL No history of CV disease
Exclusion Criteria Patients who have used any lipid-
lowering Post-menopausal hormone replacement
therapy Diabetes SBP >190 mmHg or DBP >100 mmHg Cancer (except basal or squamous cell
carcinoma of the skin) in the prior 5 years
Recent alcohol or drug abuse Inflammatory conditions (including, but
not limited to, severe arthritis, lupus, IBD)
Use of immunosuppressants
INTERVENTIONS
Randomization: Rosuvastatin 20mg qday Placebo
Four-week placebo-only run-in phase; those who took more than 80% of their tablets were enrolled in the trial
Follow-up visits were scheduled at 13 weeks then every 6 months after randomization until month 60
Some sites performed telephone follow-ups with patient between inperson visits Patients followed up in a close-out visit following cessation of the study
CRITICISMS
Many patients were not on optimal medical therapy for their risk factors (eg, aspirin therapy if high Framingham score)
Trial was truncated at 2 years so possible overestimation of treatment effect Did not include Asian participants, important because this group has distinct
rosuvastatin pharmacokinetics Individuals with normal HS-CRP values (eg, <2 g/L) were not studied Did not adequately address increased risk of new-onset DM
BOTTOM LINE
Rosuvastatin significantly reduces the incidence of major CV events (eg death, MI, stroke) in patients without hyperlipidemia but
elevated high sensitivity CRP.
DISCUSSION QUESTIONS
What did the JUPITER trial suggest about CRP levels and statin use?
According to the JUPITER trial, should patients without hyperlipidemia be treated with statin?
When studying rosuvastatin, why is it recommended to have Asian participants?
DISCUSSION QUESTIONS/ANSWERS
What did the JUPITER trial suggest about hsCRP levels and statin use? ANSWER: There is a strong linear association with elevated hsCRP and ischemic stroke/vascular
mortality. In patients with elevated CRP levels at an increased risk of cardiovascular events, a statin is recommended because statins lower hsCRP level.
According to the JUPITER trial, should patients without hyperlipidemia be treated with statin? ANSWER: In a patient with normal LDL level but elevated high sensitivity CRP with increased risk of
CV events, a statin is recommended When studying rosuvastatin, why is it recommended to have Asian participants?
ANSWER: Asian participants processs Rosuvastatin therapy differently. They are at increased risk of side effects, especially myopathy may be increased. Therefore, half the standard dose may be recommended.
BOARD-LIKE QUESTION
61 yo man is evaluated for annual exam and asks for advise on cardiac risk assessment. He denies any current chest pain, SOB, PND, orthopnea. He runs 4 miles ever 3 days and has never smoked. He has no medical problems and does not take any medications.Cardiovascular risk calculation using Pooled Cohort question is 7% risk of MI or CV event within 10 years.
ADAPTED from MKSAP 17
QUESTIONWhat test should be performed on this patient? A. Cardiac CT angiographyB. Cardiac CathC. Fractionated lipoprotein profileD. High sensitivity CRPE. Stress Echo
BOARD-LIKE QUESTION
Educational Objective: High-sensitivity C-reactive (hsCRP) protein level can guide treatment and cardiac risk stratification in a patient at intermediate risk of cardiovascular disease.
Key Point:- Patients with hsCRP>1 are considered
high risk- hsCRP<1 is considered low risk- There is no role in evaluating lipid
particle size and number for targeting treatment regimen
ANSWERWhat test should be performed on this patient? A. Cardiac CT angiographyB. Cardiac CathC. Fractionated lipoprotein profileD. High sensitivity CRPE. Stress Echo